Phaos Technology Holdings (Cayman) (POAS) Accumulated Expenses (2024 - 2025)
Phaos Technology Holdings (Cayman) posted quarterly Accumulated Expenses of $405231.0 for Q2 2025, up 22.61% year-on-year from $330495.2 in Q2 2024, and up 22.61% on a QoQ basis from $330495.2 in Q2 2024.
Phaos Technology Holdings (Cayman) (POAS) has 2 years of Accumulated Expenses data on file, last reported at $405231.0 in Q2 2025.
- For the quarter ending Q2 2025, Accumulated Expenses rose 22.61% year-over-year to $405231.0; the trailing twelve-month figure through Apr 2025 stood at $405231.0 (up 22.61% YoY), and the FY2025 full-year result was $414924.0, up 25.55% from the prior year.
- Accumulated Expenses for Q2 2025 stood at $405231.0, up from $330495.2 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $405231.0 in Q2 2025 and bottomed at $330495.2 in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Phaos Technology Holdings (Cayman) | 6.83 Mn | 6.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2025 | 405,231.03 |
| Apr 30, 2024 | 330,495.20 |